Literature DB >> 33367513

An innovative model for management of cardiovascular disease risk factors in the low resource setting of Cambodia.

Nazaneen Nikpour Hernandez1, Samiha Ismail2,3, Hen Heang4, Maurits van Pelt4, Miles D Witham5, Justine I Davies2,6,7.   

Abstract

Non-communicable diseases are increasing in developing countries and control of diabetes and hypertension is needed to reduce rates of the leading causes of morbidity and mortality, stroke and ischaemic heart disease. We evaluated a programme in Cambodia, financed by a revolving drug fund, which utilizes Peer Educators to manage diabetes and hypertension in the community. We assessed clinical outcomes and retention in the programme. For all people enrolled in the programme between 2007 and 2016, the average change in blood pressure (BP) and percentage with controlled hypertension (BP < 140/<90 mmHg) or diabetes (fasting blood glucose (BG) < 7mg/dl, post-prandial BG < 130 mg/dl, or HBA1C < 7%) was calculated every 6 months from enrolment.  Attrition rate in the nth year of enrolment was calculated; associations with loss to follow-up were explored using cox regression. A total of 9139 patients enrolled between January 2007 and March 2016. For all people with hypertension, mean change in systolic and diastolic BP within the first year was -15.1 mmHg (SD 23.6, P < 0.0001) and -8.6 mmHg (SD 14.0, P < 0.0001), respectively. BP control was 50.5% at year 1, peaking at 70.6% at 5.5 years. 41.3% of people with diabetes achieved blood sugar control at 6 months and 44.4% at 6.5 years.  An average of 2.3 years [SD 1.9] was spent in programme. Attrition rate within year 1 of enrolment ranged from 29.8% to 61.5% with average of 44.1% [SD 10.3] across 2008-15. Patients with hypertension were more likely to leave the program compared to those with diabetes and males more likely than females. The programme shows a substantial and sustained rate of diabetes and hypertension control for those who remain in the program and could be a model for implementation in other low middle-income settings, however, further work is needed to improve patient retention.
© The Author(s) 2020. Published by Oxford University Press on behalf of Health Policy and Planning society.

Entities:  

Keywords:  Health systems; diabetes; hypertension

Year:  2021        PMID: 33367513      PMCID: PMC8128014          DOI: 10.1093/heapol/czaa176

Source DB:  PubMed          Journal:  Health Policy Plan        ISSN: 0268-1080            Impact factor:   3.344


  38 in total

Review 1.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.

Authors: 
Journal:  Lancet       Date:  2004-01-10       Impact factor: 79.321

2.  Global inequalities in access to cardiovascular health care: our greatest challenge.

Authors:  Rohina Joshi; Stephen Jan; Yangfeng Wu; Stephen MacMahon
Journal:  J Am Coll Cardiol       Date:  2008-12-02       Impact factor: 24.094

3.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries.

Authors:  Clara K Chow; Koon K Teo; Sumathy Rangarajan; Shofiqul Islam; Rajeev Gupta; Alvaro Avezum; Ahmad Bahonar; Jephat Chifamba; Gilles Dagenais; Rafael Diaz; Khawar Kazmi; Fernando Lanas; Li Wei; Patricio Lopez-Jaramillo; Lu Fanghong; Noor Hassim Ismail; Thandi Puoane; Annika Rosengren; Andrzej Szuba; Ahmet Temizhan; Andy Wielgosz; Rita Yusuf; Afzalhussein Yusufali; Martin McKee; Lisheng Liu; Prem Mony; Salim Yusuf
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

4.  A summary of the effects of antihypertensive medications on measured blood pressure.

Authors:  Jun Wu; Aldi T Kraja; Al Oberman; Cora E Lewis; R Curtis Ellison; Donna K Arnett; Gerardo Heiss; Jean-Marc Lalouel; Stephen T Turner; Steven C Hunt; Michael A Province; D C Rao
Journal:  Am J Hypertens       Date:  2005-07       Impact factor: 2.689

5.  Unaffordable drug prices: the major cause of non-compliance with hypertension medication in Ghana.

Authors:  Kwame Ohene Buabeng; Lloyd Matowe; Jacob Plange-Rhule
Journal:  J Pharm Pharm Sci       Date:  2004-11-12       Impact factor: 2.327

6.  Offering integrated care for HIV/AIDS, diabetes and hypertension within chronic disease clinics in Cambodia.

Authors:  B Janssens; W Van Damme; B Raleigh; J Gupta; S Khem; K Soy Ty; Mc Vun; N Ford; R Zachariah
Journal:  Bull World Health Organ       Date:  2007-11       Impact factor: 9.408

7.  Health system challenges to hypertension and related non-communicable diseases prevention and treatment: perspectives from Ghanaian stakeholders.

Authors:  Amos K Laar; Alma J Adler; Agnes M Kotoh; Helena Legido-Quigley; Isabelle L Lange; Pablo Perel; Peter Lamptey
Journal:  BMC Health Serv Res       Date:  2019-10-15       Impact factor: 2.655

8.  Treating 4,000 diabetic patients in Cambodia, a high-prevalence but resource-limited setting: a 5-year study.

Authors:  Marie-Eve Raguenaud; Petros Isaakidis; Tony Reid; Say Chy; Lim Keuky; Gemma Arellano; Wim Van Damme
Journal:  BMC Med       Date:  2009-07-14       Impact factor: 8.775

9.  Identifying common barriers and facilitators to linkage and retention in chronic disease care in western Kenya.

Authors:  Beth Rachlis; Violet Naanyu; Juddy Wachira; Becky Genberg; Beatrice Koech; Regina Kamene; Jackie Akinyi; Paula Braitstein
Journal:  BMC Public Health       Date:  2016-08-08       Impact factor: 3.295

10.  Assessment of Barriers and Facilitators to the Delivery of Care for Noncommunicable Diseases by Nonphysician Health Workers in Low- and Middle-Income Countries: A Systematic Review and Qualitative Analysis.

Authors:  David J Heller; Anirudh Kumar; Sandeep P Kishore; Carol R Horowitz; Rohina Joshi; Rajesh Vedanthan
Journal:  JAMA Netw Open       Date:  2019-12-02
View more
  1 in total

1.  How to dampen the surge of non-communicable diseases in Southeast Asia: insights from a systematic review and meta-analysis.

Authors:  Manuela Fritz; Hanna Fromell
Journal:  Health Policy Plan       Date:  2022-01-13       Impact factor: 3.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.